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SUMMARY 
Schizophrenia and bipolar disorder are genetically related and their clinical features 
overlap. Schizophrenia is conceptualized as a neurodevelopmental disorder but the 
evidence for bipolar disorder is less clear. Cluster-analytic approaches reveal different 
cognitive profiles within bipolar disorder, possibly reflective of differing 
neurodevelopmental loads, which are also suggested by recent genetic and 
neuroimaging studies. Such studies suggest the potential utility of further clinical 
subcategories in bipolar disorder based on neurodevelopmental load.  
 
Background  
Schizophrenia (SCZ) and bipolar disorder (BD) have historically been considered 
different entities but they co-segregate in families and genetic studies provide 
increasing evidence that they share risk alleles (1). Biological and clinical evidence of 
shared pathophysiology among major psychiatric disorders promoted the 
development of dimensional classifications such as Research Domain Criteria 
(RDoC). However, while SCZ shows neuropsychological and biological features of a 
neurodevelopmental disorder, the evidence for BD is less clear (4). 
Neurodevelopmental disorders are characterized by early brain abnormalities, 
resulting from the impact of genetic and environmental factors on neurodevelopment. 
Such abnormalities increase the risk for the disorder, but overt symptoms may not 
become clinically manifest until a specific phase of development, when the brain 
regions involved reach functional maturity. However, subtle manifestations of 
pathology can be identified before clinical onset, presenting as delayed psychomotor 
milestones, neurological soft signs, abnormalities in sensory integration and deficits 
in several cognitive domains. These are associated with a variable degree of 
abnormalities observed in measures of brain morphology and connectivity (5). 
 
Epidemiological, neuropsychological and neuroimaging evidence 
Obstetric complications are one of the perinatal factors most strongly associated with 
SCZ while evidence of their role in BD is inconclusive (4). Some studies reported 
higher incidence and others no difference for BD patients relative to healthy controls 
(4). Mixed evidence also emerged from studies in BD high-risk offspring, though 
higher incidence was reported in a recent study, the first to include a comparison to 
healthy controls (6).  
Cognitive impairments are one of the core clinical dimensions of SCZ. They are 
present premorbidly and are reliable predictors of long-term outcome. The distributed 
topography of their functional imaging correlates has led to their conceptualisation as 
a result of connectivity pathology, sustained by neuronal cell migratory abnormalities 
which are neurodevelopmental in origin (5). Deficits span across all neurocognitive 
domains, with the most significant impairments identified for executive function, 
verbal learning and processing speed (7). The same cognitive domains are the most 
impaired in BD both in euthymic and symptomatic phases, with most of the evidence 
suggesting a similar pattern but milder overall severity compared to SCZ (7). 
However a different longitudinal trajectory seems to characterise cognitive deficits in 
the two disorders: in SCZ, both retrospective reviews of patients’ academic records 
and prospective studies showed premorbid general intellectual deficits (7) while the 
limited studies available in BD mainly reported good academic achievement in the 
years preceding illness onset (8). However, more recent studies suggest that 
examining population mean cognitive function may have masked increased risk at the 
extreme ends of premorbid scholastic achievement. Thus, in more recent studies, both 
poor and excellent school performance were associated with increased risk of later 
developing BD (9), suggesting that the timeframe of emergence of cognitive 
dysfunction may not be uniform and perhaps precede illness onset in those who 
underperform. Studies in high-risk cohorts robustly support the premorbid emergence 
of widespread cognitive impairment in SCZ (4). Evidence in BD high-risk cohorts is 
less conclusive, with some studies reporting impairments and others no differences 
compared to healthy controls (10). However, the modestly sized yet significant 
underperforming of youths at familial risk for BD identified in a recent meta-analysis 
(10) was considered to support the role of neurodevelopmental abnormalities in BD. 
The milder severity compared to SCZ high-risk populations may reflect a less 
pronounced developmental load in BD or result from possible dilution effects. In line 
with clustering analysis studies that have identified different cognitive profiles within 
BD, the results appear consistent with the existence of a BD subgroup with deficient 
pre-morbid cognitive function (10). 
Neurological soft signs have been robustly identified in SCZ (11) but inconsistently in 
in BD (4). However a recent meta-analysis demonstrated a robust increase in BD, 
only moderately less severe than that observed in SCZ (11) and their presence has 
been identified in BD high-risk offspring (6).  
In SCZ early signs of brain pathology manifest as structural brain abnormalities 
already present at illness onset (12). These are also observed in individuals at risk of 
developing the disorder (4), with a similar distribution yet milder severity compared 
to those observed at first episode. Findings are more heterogeneous in BD but meta-
analytic evidence indicates that structural brain abnormalities are also present in first 
episode BD patients, though grey matter volume deficits appear less pronounced 
compared to SCZ (12). Morphological brain abnormalities have also been described 
in BD high-risk cohorts, yet findings have been more inconsistent compared to the 
evidence in populations at high-risk for SCZ (6).  
 
Categorical and dimensional contributions to classification 
Neurodevelopmental mechanisms are therefore either less pronounced in BD than in 
SCZ, or only pertain to a subgroup of BD patients. The RDoC approach proposes 
cognitive function as a trans-diagnostic domain to evaluate pathogenetic mechanisms 
of psychiatric disorders. The use of data clustering rather than diagnostic categories 
demonstrated that cognitive functioning across patients with SCZ and BD appeared 
distributed, albeit not evenly, over different clusters, ranging from no impairment to 
global and severe (13). Patients with SCZ were disproportionately more represented 
in the global impairment cluster, while patients with BD were less frequently 
characterised by widespread cognitive dysfunction. (13). This evidence raises the 
question of whether more severe cognitive dysfunction in BD is associated with a 
clinical picture closer to schizophrenia. A recent meta-analysis examined cognitive 
dysfunction between potential BD subtypes. BD type I significantly underperformed 
BD type II across most domains, as did BD with a history of psychosis relative to BD 
without psychosis. Cognitive differences between the groups were reported to be 
significant yet modest, hence raising questions about cognitive heterogeneity within 
BD being discriminatory between BD clinical subtypes (14). 
Molecular imaging studies in schizophrenia have consistently shown increased striatal 
dopamine synthesis capacity (15). This was not observed in acute mania without 
psychosis (16). However a recent study in BD with psychosis revealed an increase in 
dopamine synthesis capacity similar to that observed in SCZ (17).  
Further evidence regarding features potentially discriminating between BD with 
psychosis and BD without psychosis derives from polygenic risk score (PRS) analysis 
of common variants. Using this method, extensive genetic sharing has been observed 
between SCZ and BD, but this is paired with growing evidence that differences 
between the two disorders also have a genetic basis (1). However a significant 
increase in SCZ PRS was observed for BP with psychosis compared to BD without 
psychosis (1) and associated with earlier age of onset (1). 
The conceptualization of cross-disorder risk has recently been expanded beyond SCZ 
and BD, as population studies have also examined intellectual disability, autistic 
spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) (5). 
For these a gradient of neurodevelopmental pathology has been suggested, indexed by 
mutational load and cognitive impairment, with intellectual disability at the most 
affected end of the spectrum and BD at the other end (5). Different clinical pictures, 
rather than representing discrete constructs, are considered to lie on a continuum 
reflecting the severity and timeframe of the insult on the affected underlying brain 
circuitry (5).  
PRS analyses capture common genetic variants but do not identify more rare ones, 
such as copy number variants (CNV). The latter were reported to be distributed along 
a gradient of frequency from ASD and intellectual disability at one end and BD at the 
other end of the spectrum (5). Large CNVs are significantly less strongly associated 
with BD relative to SCZ (18) but some evidence, albeit not definitive, suggests that 
they are particularly enriched among BD patients with early onset and greater 
cognitive impairment (5). This is in line with the idea of a broad neurodevelopmental 
gradient but also highlights the known heterogeneity within BD, again likely 
reflective of a greater neurodevelopmental load in a subgroup of BD patients.  
  
Conclusions 
Consistent with the idea of a neurodevelopmental continuum, evidence suggests that 
at least a subgroup of BD patients demonstrate early cognitive impairment, 
documented premorbidly and associated with a higher burden of large CNVs (5, 19). 
It is currently unclear whether early features of a neurodevelopmental disorder are 
associated with a specific phenotype in adulthood. We might hypothesise that 
individuals with a more pronounced set of childhood developmental features are more 
likely to develop BD with psychotic symptoms and a neurobiology closer to 
schizophrenia, in line with molecular imaging and genetic findings. Work on 
transdiagnostic dimensions highlights neurodevelopmental continuity between 
previously distinct constructs, with intellectual disability at one end of the spectrum 
and BD at the other end. This work might also lead to identifying more homogenous 
and valid subcategories within the currently broadly defined disorders. This appears 
to be a critical step in bringing diagnostics closer to the underlying biological 
mechanisms.  
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